FDA fast-tracks Daiichi Sankyo & Merck lung cancer drug review

The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis

Haemonetics gains FDA nod to expand VASCADE MVP XL for larger sheaths in heart procedures

The approval now covers procedures using 10-14F inner diameter and up to 17F outer diameter procedural sheaths

Johnson & Johnson unveils Varipulse Pro in Europe for faster & safer heart procedures

The new device promises faster, more efficient cardiac procedures while maintaining the safety and effectiveness clinicians expect

Sun Pharma flags mixed Fibromun trial results, advances new Phase III study in soft tissue sarcoma

The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy

Kauvery Hospital sets new benchmark in high-risk cardiac care

71-year-old high-risk patient with atrial fibrillation and ventricular tachycardia discharged next day

Q2 2026 drug catalysts put Replimune, Arvinas and Boehringer in sharp focus: GlobalData

Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning

Alembic Pharmaceuticals partners with Enthral.ai for learning and training management of its 9000+ learners

Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows

Orca Bio’s Orca-T FDA review extended to July 2026

Bristol Myers Squibb expands groundbreaking program to close faps in multiple myeloma care

The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners

Otsuka Pharma to acquire Transcend Therapeutics in $1.225 billion deal

Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones